natgillin/translations-raw huggingface dataset:
Gastrointestinal perforation has been reported in patients treated with tacrolimus. 
Pri bolnikih, zdravljenih s takrolimusom, so poročali o perforaciji prebavil.
Envarsus 1 mg prolonged-release tablets Each prolonged-release tablet contains 1 mg tacrolimus (as monohydrate). 
Envarsus 1 mg tablete s podaljšanim sproščanjem Ena tableta s podaljšanim sproščanjem vsebuje 1 mg takrolimusa (v obliki monohidrata).
Rare side effects (may affect up to 1 in 1,000 people): - Small bleedings in your skin due to blood clots - Increased muscle stiffness - Blindness, deafness 
Zelo redki neželeni učinki (pojavijo se lahko pri največ 1 od 10.000 bolnikov): - mišična oslabelost
Very rare Not known 
Neznani neželeni učinki (pogostnost ni znana):
CYP3A4 inducers potentially leading to decreased tacrolimus blood levels Clinically, the following substances have been shown to decrease tacrolimus blood levels: Interactions have been observed with rifampicin, phenytoin, and St. John's Wort (Hypericum perforatum) which may require increased tacrolimus doses in almost all patients. 
Induktorji CYP3A4, ki lahko povzročijo zmanjšane ravni takrolimusa v krvi Klinično je ugotovljeno, da koncentracijo takrolimusa v krvi zmanjšujejo naslednje snovi:
Envarsus 4 mg prolonged-release tablets 
Envarsus 4 mg tablete s podaljšanim sproščanjem
Italy or 
Italija ali
At the molecular level, the effects of tacrolimus appear to be mediated by binding to a cytosolic protein (FKBP12) which is responsible for the intracellular accumulation of the compound. 
(FKBP12), ki je odgovorna za njegovo znotrajcelično kopičenje.
- Collection of fluid around the heart - Acute breathlessness - Cyst formation in your pancreas, pre-stage of a blockage in your bowel - Problems with blood flow in the liver - Serious illness with blistering of skin, mouth, eyes and genitals; - Increased hairiness - Thirst, fall, feeling of tightness in your chest, decreased mobility, ulcer 
- resno obolenje s pojavom mehurjev na koži, ustih, očeh in spolovilih - močnejša poraščenost - žeja, padci, občutek tiščanja v prsih, zmanjšana gibljivost, razjeda
- The need for specialist supervision and monitoring if there is a clinical decision to switch a patient to another tacrolimus containing products. 
- Pri klinični odločitvi o prehodu bolnika na drugo zdravilo, ki vsebuje takrolimus, mora zdravljenje nadzirati in spremljati specialist.
Envarsus 1 mg prolonged-release tablets tacrolimus 
Envarsus 1 mg tablete s podaljšanim sproščanjem tacrolimus
Envarsus 4 mg prolonged-release tablets tacrolimus 
Envarsus 4 mg tablete s podaljšanim sproščanjem tacrolimus
Envarsus contains the active substance tacrolimus. 
Zdravilo Envarsus vsebuje učinkovino takrolimus, ki je imunosupresiv.
Envarsus 1 mg prolonged-release tablets 
Envarsus 1 mg tablete s podaljšanim sproščanjem
and combination tablets, used to treat HIV infection - HCV protease inhibitors (e.g. telaprevir, boceprevir, and the combination ombitasvir/paritaprevir/ritonavir with or without dasabuvir), used to treat hepatitis C - nilotinib and imatinib (used to treat certain cancers) - mycophenolic acid, used to suppress the immune system to prevent transplant rejection - medicines for stomach ulcer and acid reflux (e.g. omeprazole, lansoprazole or cimetidine) - antiemetics, used to treat nausea and vomiting (e.g. metoclopramide) - cisapride or the antacid magnesium-aluminium-hydroxide, used to treat heartburn - the contraceptive pill or other hormone treatments with ethinylestradiol, hormone treatments with danazol - medicines used to treat high blood pressure or heart problems (e.g. nifedipine, nicardipine, 
- protiglivična zdravila in antibiotiki, zlasti t. i. makrolidni antibiotiki, ki se uporabljajo za zdravljenje okužb (npr. ketokonazol, flukonazol, itrakonazol, vorikonazol, klotrimazol in izavukonazol, eritromicin, klaritromicin, josamicin, izoniazid in rifampicin) - zaviralci proteaz HIV (npr. ritonavir, nelfinavir, sakvinavir), stopnjevalno zdravilo kobicistat in kombinirane tablete, ki se uporabljajo za zdravljenje okužbe z virusom HIV - zaviralci proteaze HCV (npr. telaprevir, bokeprevir in kombinacija ombitasvir/paritaprevir/ritonavir z dasabuvirjem ali brez njega), ki se uporabljajo za zdravljenje okužbe z virusom hepatitisa C - nilotinib in imatinib (ki se uporabljata za zdravljenje določenih vrst raka)
Renal and urinary disorders renal impairment renal failure, renal failure acute, nephropathy toxic, renal tubular necrosis, urinary abnormalities, oliguria, bladder and urethral symptoms haemolytic uraemic syndrome, anuria nephropathy , cystitis haemorrhag ic 
nepravilnosti v sečilih, oligurija, simptomi sečnega mehurja in sečnice hemolitičnouremični sindrom, anurija nefropatija, hemora gični cistitis
Very common side effects (may affect more than 1 in 10 people): - increased blood sugar, diabetes mellitus, increased potassium in the blood - difficulty in sleeping - trembling, headache - increased blood pressure - liver function tests abnormal - diarrhoea, nausea - kidney problems 
- povečanje vrednosti krvnega sladkorja, sladkorna bolezen, zvišanje vrednosti kalija v krvi - težave s spanjem - tresenje, glavobol
Other interactions potentially leading to increased tacrolimus blood levels Tacrolimus is extensively bound to plasma proteins. 
Drugo medsebojno delovanje, ki lahko povzroči zvišane ravni takrolimusa v krvi
Envarsus is a once-a-day oral formulation of tacrolimus. 
Zdravilo Envarsus je peroralna farmacevtska oblika takrolimusa, ki se ga jemlje enkrat na dan.
For these reasons, the combined administration of ciclosporin and tacrolimus is not recommended, and care should be taken when administering tacrolimus to patients who have previously received ciclosporin (see sections 4.2 and 4.4). 
Zato kombinirana uporaba ciklosporina in takrolimusa ni priporočljiva; pri bolnikih, ki so prej dobivali ciklosporin, je treba takrolimus uporabiti previdno
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS ALUMINIUM FOIL WRAPPER 
OVOJNINAH OVITEK IZ ALUMINIJASTE FOLIJE
hallucination, mental disorders - fits, disturbances in consciousness, tingling and numbness (sometimes painful) in the hands and feet, dizziness, impaired writing ability, nervous system disorders - blurred vision, increased sensitivity to light, eye disorders - ringing sound in your ears - reduced blood flow in the heart vessels, faster heartbeat - bleeding, partial or complete blocking of blood vessels, reduced blood pressure - shortness in breath, disorders of the respiratory tissues in the lung, collection of liquid around the lung, inflammation of the pharynx, cough, flu-like symptoms - stomach problems such as inflammation or ulcer causing abdominal pain or diarrhoea, bleeding in the stomach, inflammation or ulcer in the mouth, collection of fluid in the belly, vomiting, 
- sopenje, spremembe v pljučnem tkivu, nabiranje tekočine okrog pljuč, vnetje žrela, kašelj, gripi podobni simptomi - vnetja ali razjede s posledično bolečino v trebuhu ali drisko, krvavitve v želodcu, vnetje ali razjede v ustni votlini, nabiranje tekočine v trebušni votlini, bruhanje, bolečine v trebuhu, slaba prebava, zaprtje, vetrovi, napenjanje, mehko blato
Talk to your doctor before taking Envarsus: - if you have, or have had, liver problems. 
Posvetujte se z zdravnikom, preden vzamete zdravilo Envarsus:
Unknown side effects (frequency not known): - Cases of pure red cell aplasia (a very severe reduction in red blood cell counts), - Agranulocytosis (a severely lowered number of white blood cells) - Haemolytic anaemia (decreased number of red blood cells due to abnormal breakdown) - Abnormality of the optic nerve (optic neuropathy) 
- primeri čiste aplazije rdečih krvnih celic (zelo resno zmanjšanje števila rdečih krvnih celic)
Gastrointestinal disorders 
Bolezni endokrinega sistema hirzutizem
Therefore, you should not breast-feed whilst taking Envarsus. 
Med jemanjem zdravila Envarsus je treba zato prenehati z dojenjem.
Hypromellose 
hemolitična anemija
Among the most frequent adverse reactions (at least in 2% of patients) in clinical studies in liver transplant patients receiving Envarsus were tremor, headache, fatigue, hyperkalaemia, hypertension, renal failure, blood creatinine increased, dizziness, hepatitis C, muscle spasms, tinea infection, leukopenia, sinusitis, and upper respiratory tract infections (URTI), all of which are known to occur in the respective patient population under immunosuppressive treatment. 
hepatitis C, mišični spazmi, okužba s tineo, levkopenija, sinusitis in okužbe zgornjih dihal, za katere je znano, da se pri imunosupresivnem zdravljenju pojavljajo pri zadevni populaciji bolnikov.
Excipients 
Advagraf).
Invented Name 
EU številka Izmišljen o ime
These side effects were generally of mild or moderate severity. 
Ti neželeni učinki so bili večinoma blagi ali zmerni.
The recommended dose is 1,500 mg, given either as a single infusion or as 1,000 mg in the first week followed by 500 mg one week later. 
Priporočeni odmerek zdravila je 1 500 mg, ki se daje bodisi kot enkratna infuzija bodisi kot 1 000 mg infuzija v prvem tednu in 500 mg infuzija teden dni kasneje.
In the 3 studies, between 87% and 94% of patients treated with Xydalba were cured, compared with between 91% and 93% of patients treated with any of the two comparators. 
V navedenih treh študijah je ozdravelo od 87 do 94 % bolnikov, ki so jih zdravili z zdravilom Xydalba, v primerjavi z 91 do 93 % bolnikov, ki so jih zdravili z enim od obeh primerjalnih zdravil.
In all the studies, the main measure of effectiveness was the number of patients whose infection was cured after treatment. 
Glavno merilo učinkovitosti v vseh študijah je bilo število bolnikov, pri katerih je bila okužba po zdravljenju ozdravljena.
The European Commission granted a marketing authorisation valid throughout the European Union for Xydalba on 19 February 2015. 
Evropska komisija je dovoljenje za promet z zdravilom Xydalba, veljavno po vsej Evropski uniji, izdala 19. februarja 2015.
What measures are being taken to ensure the safe and effective use of Xydalba? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Xydalba?
Xydalba is given once a week by an infusion lasting 30 minutes. 
Zdravilo Xydalba se daje enkrat tedensko v obliki infuzije, ki traja 30 minut.
The full EPAR and risk management plan summary for Xydalba can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Xydalba sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Patients who received vancomycin and responded to treatment had the option to switch to linezolid after 3 days. 
Bolniki, ki so prejemali vankomicin in so se odzvali na zdravljenje, so lahko po treh dneh prešli na jemanje linezolida.
This is a summary of the European public assessment report (EPAR) for Xydalba. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Xydalba.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Xydalba's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Xydalba večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
It works by preventing certain bacteria from making their own cell walls, thereby killing the bacteria. 
Deluje tako, da prepreči, da bi si določene bakterije zgradile celične stene, s čimer jih uniči.
In light of the need for new antibiotics targeting multi-resistant bacteria, the CHMP concluded that Xydalba, which showed activity against certain bacteria resistant to other antibiotics, could be a valuable alternative treatment option. 
Odbor je ob upoštevanju potrebe po novih antibiotikih, ki delujejo proti večkratno odpornim bakterijam, zaključil, da je zdravilo Xydalba, ki se je izkazalo za učinkovito proti nekaterim bakterijam, odpornim proti drugim antibiotikom, lahko dragocena nadomestna možnost zdravljenja.
A risk management plan has been developed to ensure that Xydalba is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Xydalba je bil pripravljen načrt obvladovanja tveganj.
The active substance in Xydalba, dalbavancin, is a type of antibiotic called glycopeptide. 
Zdravilna učinkovina v zdravilu Xydalba, dalbavancin, je vrsta antibiotika, ki ga imenujemo glikopeptid.
What benefits of Xydalba have been shown in studies? 
Kakšne koristi je zdravilo Xydalba izkazalo v študijah?
Before using Xydalba, doctors should consider official guidance on the appropriate use of antibiotics. 
Preden zdravnik predpiše zdravilo Xydalba, mora upoštevati uradne smernice za ustrezno uporabo antibiotikov.
What are the risks associated with Xydalba? 
Kakšna tveganja so povezana z zdravilom Xydalba?
What is Xydalba and what is it used for? 
Kaj je zdravilo Xydalba in za kaj se uporablja?
It contains the active substance dalbavancin. 
Vsebuje zdravilno učinkovino dalbavancin.
Xydalba was at least as effective as vancomycin or linezolid at curing the infection. 
Zdravilo Xydalba je bilo pri ozdravljenju okužbe vsaj tako učinkovito kot vankomicin ali linezolid.
Other information about Xydalba 
Druge informacije o zdravilu Xydalba
The most common side effects with Xydalba (which may affect between 1 and 3 people in 100) are nausea (feeling sick), diarrhoea and headache. 
Najpogostejši neželeni učinki zdravila Xydalba (ki lahko prizadenejo od 1 do 3 osebe od 100) so navzeja (slabost), glavobol, driska in glavobol.
A list of bacteria against which Xydalba is active can be found in the summary of product characteristics (also part of the EPAR). 
Seznam bakterij, proti katerim je zdravilo Xydalba učinkovito, je na voljo v povzetku glavnih značilnosti zdravila (ki je prav tako del EPAR).
For more information about treatment with Xydalba, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Xydalba preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Why is Xydalba approved? 
Zakaj je bilo zdravilo Xydalba odobreno?
For the full list of all side effects and restrictions with Xydalba, see the package leaflet. 
Za celoten seznam vseh neželenih učinkov in omejitev pri uporabi zdravila Xydalba glejte navodilo za uporabo.
Xydalba is an antibiotic used in adults to treat acute (short-term) bacterial infections of the skin and of skin structures (tissue below the skin) such as cellulitis (inflammation of the deep skin tissue), skin abscesses and wound infections. 
Zdravilo Xydalba je antibiotik, ki se uporablja pri odraslih za zdravljenje akutnih (kratkotrajnih) bakterijskih okužb kože in kožnih struktur (podkožnega tkiva), kot so celulitis (vnetje globokega podkožnega tkiva), kožni abscesi in okužbe ran.
Xydalba was compared with vancomycin (another glycopeptide) or with linezolid (an antibiotic that can be taken by mouth) in three main studies involving a total of around 2,000 patients with serious infections of the skin and soft tissue under the skin, such as cellulitis, skin abscesses and wound infections. 
Zdravilo Xydalba so primerjali z vankomicinom (drugim glikopeptidom) ali linezolidom (antibiotikom, ki se lahko jemlje peroralno) v treh glavnih študijah, v katerih je sodelovalo skupno približno 2 000 bolnikov z resnimi okužbami kože in mehkega podkožnega tkiva, kot so celulitis, abscesi kože in okužbe rane.
For practical information about using Xydalba, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Xydalba naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Dalbavancin has been shown to work against bacteria (such as methicillin resistant Staphylococcus aureus (MRSA)) 
Dalbavancin je dokazano učinkovit proti bakterijam (na primer proti na meticilin odporni bakteriji Staphylococcus aureus (MRSA)), proti katerim običajni antibiotiki ne delujejo.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Xydalba, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Xydalba is available as a powder to be made up into a solution for infusion (drip) into a vein and can only be obtained with a prescription. 
Zdravilo Xydalba je na voljo v obliki praška za pripravo raztopine za infundiranje (kapalne infuzije) v veno in se izdaja le na recept.
It is not intended to provide practical advice on how to use Xydalba. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Xydalba's safety profile is comparable to that of other antibiotics of the glycopeptide class; side effects affecting hearing and kidney function, which are typical for glycopeptides, have not been shown with the proposed regimens of Xydalba in the clinical trials. 
Varnostni profil zdravila Xydalba je primerljiv z varnostnim profilom drugih glikopeptidnih antibiotikov, pri čemer v kliničnih preskušanjih ob zdravljenju z zdravilom Xydalba po predlaganih režimih niso opazili neželenih učinkov na sluh in delovanje ledvic, ki so sicer značilni za glikopeptide.
How is Xydalba used? 
Kako se zdravilo Xydalba uporablja?
How does Xydalba work? 
Kako zdravilo Xydalba deluje?
The dose of Xydalba needs to be reduced in patients with severely impaired kidney function. 
Pri bolnikih s hudo okvaro delovanja ledvic je odmerek včasih treba zmanjšati.
The main measure of effectiveness was the rate of implantation and pregnancy. 
Glavno merilo učinkovitosti je bil delež vsaditev in nosečnosti.
What measures are being taken to ensure the safe and effective use of Rekovelle? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Rekovelle?
The full EPAR for Rekovelle can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Rekovelle je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
It is not intended to provide practical advice on how to use Rekovelle. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
What benefits of Rekovelle have been shown in studies? 
Kakšne koristi je zdravilo Rekovelle izkazalo v študijah?
The frequency of side effects may decrease with repeated treatment cycles. 
Pogostnost neželenih učinkov se s ponavljanjem ciklov zdravljenja lahko zmanjša.
After the first injection, the woman or their partner may be able to give the injections themselves, if they have been trained and have access to expert advice. 
Po prvi injekciji si injekcijo lahko daje ženska sama oziroma njen partner, če sta bila za to usposobljena in imata dostop do izvedenskega svetovanja.
This is a summary of the European public assessment report (EPAR) for Rekovelle. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Rekovelle.
What is Rekovelle and what is it used for? 
Kaj je zdravilo Rekovelle in za kaj se uporablja?
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Rekovelle's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Rekovelle večje od z njim povezanih tveganj in priporočil, da se odobri za uporabo v EU.
The dose can then be modified in subsequent cycles according to the woman's response. 
Odmerek se nato v naslednjih ciklih prilagodi glede na odziv ženske.
The safety profile of Rekovelle was considered acceptable and similar to that of GONAL-f. 
Varnostni profil zdravila Rekovelle je bil ocenjen kot sprejemljiv in je podoben varnostnemu profilu zdravila GONAL-f.
Rekovelle is given by injection under the skin once a day for several consecutive days during the woman's menstrual cycle starting on day 2 or 3 of the cycle and is continued until sufficient eggs have developed. 
Zdravilo Rekovelle se daje z injekcijo pod kožo enkrat na dan več dni zaporedoma v času menstrualnega cikla s pričetkom na 2. ali 3. dan cikla in se nadaljuje, dokler se ne razvije dovolj jajčec.
Other information about Rekovelle 
Druge informacije o zdravilu Rekovelle
What are the risks associated with Rekovelle? 
Kakšna tveganja so povezana z zdravilom Rekovelle?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rekovelle have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo tega zdravila upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Why is Rekovelle approved? 
Zakaj je bilo zdravilo Rekovelle odobreno?
The study showed that Rekovelle was as effective as GONAL-f at stimulating the ovaries: around 31% of women (204 out of 665) treated with Rekovelle became pregnant compared with around 32% of women (209 out of 661) treated with GONAL-f. Implantation rates were also similar: around 35% with Rekovelle versus around 36% with GONAL-f. 
Študija je pokazala, da je zdravilo Rekovelle enako učinkovito kot zdravilo GONAL-f pri stimulaciji jajčnikov: zanosilo je približno 31 % žensk (204 od 665), zdravljenih z zdravilom Rekovelle, v primerjavi s približno 32 % žensk (209 od 661), zdravljenih z zdravilom GONAL-f.
The medicine can only be obtained with a prescription and treatment should be started under the supervision of a doctor who has experience in the treatment of fertility problems. 
Predpisovanje in izdaja zdravila je le na recept, zdravljenje z njim pa se sme uvesti samo pod nadzorom zdravnika z izkušnjami z zdravljenjem težav s plodnostjo.
For more information about treatment with Rekovelle, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Rekovelle preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The most common side effects with Rekovelle (which may affect between 1 and 10 people in 100) are headache, discomfort and pain in the pelvic area which may arise from the ovaries, nausea (feeling sick) and tiredness and ovarian hyperstimulation syndrome (OHSS). 
Najpogostejši neželeni učinki zdravila Rekovelle (ki se lahko pojavijo pri od 1 do 10 bolnic od 100) so glavobol, neugodje in bolečina v medeničnem predelu, ki lahko izhaja iz jajčnikov, slabost (siljenje na bruhanje) in utrujenost ter sindrom hiperstimulacije jajčnikov.
The starting dose of Rekovelle depends on the woman's bodyweight and on the blood level of the anti-Müllerian hormone (a hormone which indicates how well the ovaries will respond to stimulation). 
Začetni odmerek zdravila Rekovelle je odvisen od telesne mase ženske in ravni antiMüllerjevega hormona (hormona, ki kaže, kako dobro se bodo jajčniki odzvali na stimulacijo) v krvi.
How is Rekovelle used? 
Kako se zdravilo Rekovelle uporablja?
For practical information about using Rekovelle, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Rekovelle naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
In severe cases OHSS may lead to difficulty breathing and problems with blood clotting. 
V resnih primerih lahko sindrom hiperstimulacije jajčnikov privede do težav z dihanjem in motenj strjevanja krvi.